ライフサイエンスコーパス: hepatitis B vaccine

1 he highest levels of antibody titers against hepatitis B vaccine.

2 >/=6 months using 3 doses of plasma-derived hepatitis B vaccine.

3 pants were randomized to receive Na-ASP-2 or hepatitis B vaccine.

4 ticipants received 3 doses of plasma-derived hepatitis B vaccine.

5 anti-HBs) received vaccination with standard hepatitis B vaccine.

6 an after the introduction of the recombinant hepatitis B vaccine.

7 Controls received hepatitis B vaccine.

8 mounted a more robust CD4 T cell response to hepatitis B vaccine.

9 All participants received 3 doses of hepatitis B vaccine.

10 antigens spanning pertussis, diphtheria and hepatitis B vaccines.

11 omplete nonresponders to currently available hepatitis B vaccines.

12 but concurrent injections of hepatitis A and hepatitis B vaccines.

13 e immunized with 1 of 2 licensed recombinant hepatitis B vaccines.

14 Of the 60 cases, 46 had received hepatitis B vaccines.

15 /ml received one booster dose of recombinant hepatitis B vaccine 2-4 weeks later and were then evalua

16 IU/mL received 1 booster dose of recombinant hepatitis B vaccine 2-4 weeks later and were then evalua

17 patitis C) received 3 doses of a recombinant hepatitis B vaccine, according to a 0-, 1-, and 6-month

18 cine adjuvanted with potassium alum, a human hepatitis B vaccine adjuvanted with aluminum hydroxide,

19 efficacy of immunity induced by a commercial hepatitis B vaccine against a tissue culture-derived, cl

20 To determine the protection afforded by hepatitis B vaccine, Alaska Native persons who had recei

21 out one half of centers routinely administer hepatitis B vaccine and approximately three quarters imm

22 Introduction of the birth dose of hepatitis B vaccine and improving access and affordabili

23 ect of a universal newborn immunization with hepatitis B vaccine and mass population screening immuni

24 ls <10 mIU/mL received 1 dose of recombinant hepatitis B vaccine and were evaluated on the basis of a

25 Survey 2005-2016 who reported three doses of hepatitis B vaccine and were seropositive for anti-hepat

26 motif are potentially useful as alternative hepatitis B vaccines and as diagnostic reagents for the

27 relationship between antibody response to a hepatitis-B vaccine and body height, with a positive rel

28 s of age in 1998 received 3 or more doses of hepatitis B vaccine, and 79.9% completed the 4:3:1:3 vac

29 mmended three-dose regimen of plasma-derived hepatitis B vaccine, and 94% demonstrated antibody to he

30 may be associated with impaired responses to hepatitis B vaccine, and evaluation of strategies to imp

31 ptheria-tetanus-acellular pertussis vaccine, hepatitis B vaccine, and in some children Haemophilus in

32 igen genes and responsiveness to measles and hepatitis B vaccines are discussed, along with the influ

33 The trial administered a licensed Hepatitis B vaccine at 0, 1 and 6 months.

34 up consisted of 3 doses of 40 ug recombinant hepatitis B vaccine at 0, 1, and 2 months.

35 le sclerosis associated with exposure to the hepatitis B vaccine at any time before the onset of the

36 portion of US infants who received dose 1 of hepatitis B vaccine at birth declined from 47% among tho

37 Administration of the first dose of hepatitis B vaccine at birth is associated with increase

38 ted in September 1999 when preservative-free hepatitis B vaccine became available.

39 ion safety policy, but the policy for timely hepatitis B vaccine birth dose and hepatitis B vaccinati

40 ame region; 18.8% more children received the hepatitis B vaccine birth dose and the hepatitis B virus

41 nd only 3% of newborn children are given the hepatitis B vaccine birth dose.

42 Reductions in hepatitis B vaccine birth-dose coverage persisted after

43 Coverage with 3 doses of hepatitis B vaccine by 19 months of age declined from 88

44 sponse to currently available single-antigen hepatitis B vaccines confirmed by measuring hepatitis B

45 In healthy normal adults, a triple antigen hepatitis B vaccine containing S and pre-S antigens prod

46 These data suggest that immunization with hepatitis B vaccine continues to provide high levels of

47 ed either HEV239 (HEV239 group) or Hepa-B (a hepatitis B vaccine; control group).

48 Hepatitis B vaccine coverage was 93% among 567 children

49 Long-lasting protection resulting from hepatitis B vaccine, despite loss of antibody against he

50 ompared with children who received the first hepatitis B vaccine dose within 7 days of birth, odds ra

51 s, polio, Haemophilus influenzae type b, and hepatitis B vaccine (DTaP/IPV/Hib/HepB) and 2 doses of m

52 by primary immunization with plasma-derived hepatitis B vaccine during childhood and adulthood lasts

53 by primary immunization with plasma-derived hepatitis B vaccine during childhood and adulthood lasts

54 s in viral genetic diversity as a measure of hepatitis B vaccine effectiveness has major limitations.

55 Alum-adjuvanted hepatitis B vaccine elicited vital signs and inflammator

56 in all groups (35.5% of all doses), with the hepatitis B vaccine eliciting fewer injection-site sympt

57 les induced by hepatitis A vaccine (Havrix), hepatitis B vaccine (Engerix-B), and hepatitis A and B c

58 rix vaccine) or control vaccine formulation (hepatitis B vaccine FENDrix) and subsequently challenged

59 ated at birth retain immunological memory to hepatitis B vaccine for 15 years, but those who did not

60 for adults younger than 50 year of age, and hepatitis B vaccine for adults without a risk factor.

61 types required measles, mumps, rubella, and hepatitis B vaccines for entering students; varicella va

62 Follow-up studies of recipients of hepatitis B vaccine from endemic areas have reported los

63 to each other and to hepatitis A vaccine and hepatitis B vaccine given separately and concurrently wa

64 Hepatitis B vaccine has been included in the infant immu

65 lmette-Guerin (BCG) vaccine, Triple vaccine, Hepatitis B vaccine (HBV), Polio, Measles, Rubella, Mump

66 d's infants have access to the birth dose of hepatitis B vaccine (HBV), which prevents mother-to-chil

67 A single dose of the new triple-antigen hepatitis B vaccine (Hepacare) produced a successful res

68 de novo immune response against recombinant hepatitis B vaccine (HepB-CpG) and recall response again

69 teers (18-45 years old) received recombinant hepatitis B vaccine IM at 0, 1, and 6 months and were ra

70 from a cohort vaccinated with plasma-derived hepatitis B vaccine in 1981 who have been followed perio

71 SiVET participants received a licensed Hepatitis B vaccine in a schedule (0, 1 and 6 months) si

72 g dialysis who received at least 1 dose of a hepatitis B vaccine in either family medicine or interna

73 cularly promising for birth dose delivery of hepatitis B vaccine in resource-constrained regions.

74 olvable microneedle patch (dMNP) delivery of hepatitis B vaccine in rhesus macaques and provides evid

75 epatitis A vaccine with that of a commercial hepatitis B vaccine in subjects with chronic hepatitis C

76 Hepatitis B vaccine is an effective measure to prevent h

77 antigen (anti-HBc) should be vaccinated with hepatitis B vaccine is not certain.

78 sive drugs, serum albumin, lymphocyte count, hepatitis B vaccine nonresponder status, and dialysis vi

79 ding health care workers) resulting from the hepatitis B vaccine primary series is unknown.

80 rrent and expanding worldwide application of hepatitis B vaccine promises to eliminate and eventually

81 benefits of hepatitis B immune globulin and hepatitis B vaccine prophylaxis of newborns of hepatitis

82 Hepatitis B vaccine provides a model for improving uptak

83 plasma-derived and yeast-derived recombinant hepatitis B vaccines represents a major contribution to

84 t European and US guidelines for recombinant hepatitis B vaccine (rHBV) after hematopoietic-cell tran

85 OVID-19 mRNA (ROR, 13.41; IC(025), 2.90) and hepatitis B vaccines (ROR, 11.35; IC(025), 3.18).

86 Countries welcomed the introduction of hepatitis B vaccine, safe injection equipment, and the f

87 s ratios (ORs) for not completing the 3-dose hepatitis B vaccine series among children who received t

88 and >/=55 years were more likely to initiate hepatitis B vaccine series compared with those aged 18-2

89 ion of chimpanzees with licensed recombinant hepatitis B vaccines stimulates anti-HBs that is broadly

90 y to lack of evidence, including double-dose hepatitis B vaccine, timing of influenza immunization in

91 onsistency lots of a combination hepatitis A/hepatitis B vaccine to each other and to hepatitis A vac

92 1981, we used three doses of plasma-derived hepatitis B vaccine to immunize a cohort of 1578 Alaska

93 In hepatitis B vaccine trials in Amsterdam, New York City,

94 ctiveness of implementing ambient storage of hepatitis B vaccines under a controlled temperature chai

95 Present hepatitis B vaccines use multidose prolonged regimens, w

96 HEV vaccine) or a control vaccine (Hepa-B, a hepatitis B vaccine), using block randomisation with ran

97 A hepatitis B vaccine was administered to 66 young Latvian

98 The efficacy of 10-microg and 40-microg hepatitis B vaccines was compared with that of an invest

99 t study, the protective efficacy of licensed hepatitis B vaccines was evaluated against challenge wit

100 tive persons who had received plasma-derived hepatitis B vaccine when they were >6 months of age were

101 wing at least 5 doses of aluminum-adjuvanted hepatitis B vaccine who received the 2-dose Heplisav-B (

102 The 2-dose hepatitis B vaccine with a cytosine phosphoguanine adjuv

103 ion in prelicensure trials than did a 3-dose hepatitis B vaccine with an aluminum hydroxide adjuvant

104 ad previously completed two 3-dose series of hepatitis B vaccine without achieving a protective level

105 that GM-CSF given intramuscularly (IM) with hepatitis B vaccine would result in increased seroconver